{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:30:44Z","timestamp":1771849844845,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.annder.2024.103300","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T01:40:08Z","timestamp":1721180408000},"page":"103300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vitiligo treated with oral baricitinib and heliotherapy: A case series"],"prefix":"10.1016","volume":"151","author":[{"given":"R.","family":"Reviron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5772-3504","authenticated-orcid":false,"given":"E.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-8869","authenticated-orcid":false,"given":"A.","family":"Bertolotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103300_b0005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Ezzedine K. Vitiligo: A Review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2024.103300_b0010","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/bjd.15933","article-title":"Quality of life in people with vitiligo: a systematic review and meta-analysis","volume":"177","author":"Morrison","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103300_b0015","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm","volume":"37","author":"van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103300_b0020","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103300_b0025","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2024.103300_b0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ajd.13348","article-title":"Repigmentation of vitiligo with oral baricitinib","volume":"61","author":"Mumford","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2024.103300_b0035","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103300_b0040","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid repigmentation of vitiligo using tofacitinib plus low-dose","volume":"154","author":"Kim","year":"2018","journal-title":"Narrowband UV-B Phototherapy JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103300_b0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103300_b0050","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T22:42:59Z","timestamp":1726785779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963824000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0151963824000565"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103300","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo treated with oral baricitinib and heliotherapy: A case series","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103300"}}